The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: An initial analysis

BJU International

Volumn 99, Issue 4, 2007, Pages 786-793

  Shukla Dave, Amita ^a   Hricak, Hedvig ^a   Kattan, Michael W ^b   Pucar, Darko ^a   Kuroiwa, Kentaro ^a,c   Chen, Hui Ni ^a   Spector, Jessica ^a   Koutcher, Jason A ^a   Zakian, Kristen L ^a   Scardino, Peter T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Magnetic resonance spectroscopic imaging; MRI; Nomogram; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PATIENT COUNSELING; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

AGED; BIOPSY, NEEDLE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; ROC CURVE;

EID: 33947304021     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06689.x     Document Type: Article

References (36)

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-9
2. Draisma G, Boer R, Otto SJ et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78
3. Etzioni R, Penson DF, Legler JM et al. Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 2002; 94: 981-90
4. Epstein JI, Sanderson H, Carter HB, Scharfstein DO. Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy. Urology 2005; 66: 356-60
5. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74
6. Villers A, McNeal JE, Freiha FS, Stamey TA. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992; 70: 2313-8
7. Carter HB, Sauvageot J, Walsh PC, Epstein JI. Prospective evaluation of men with stage T1c adenocarcinoma of the prostate. J Urol 1997; 157: 2206-9
8. Douglas TH, McLeod DG, Mostofi FK et al. Prostate-specific antigen-detected prostate cancer (stage T1c). an analysis of whole-mount prostatectomy specimens. Prostate 1997; 32: 59-64
9. Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens - a different view. J Urol 1997; 157: 244-50
10. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998; 160: 2407-11
11. Goto Y, Ohori M, Arakawa A, Kattan MW, Wheeler TM, Scardino PT. Distinguishing clinically important from unimportant prostate cancers before treatment: value of systematic biopsies. J Urol 1996; 156: 1059-63
12. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996; 155: 816-20
13. Khan MA, Partin AW. Expectant management: an option for localized prostate cancer. Prostate Cancer Prostatic Dis 2005; 8: 311-5
14. Noguchi M, Stamey TA, McNeal JE, Yemoto CM. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer. J Urol 2001; 166: 104-10
15. Kattan MW, Eastham JA, Wheeler TM et al. Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. J Urol 2003; 170: 1792-7
16. Partin AW, Kattan MW, Subong EN et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445-51
17. Akin O, Sala E, Moskowitz CS et al. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. Radiology 2006; 239: 784-92
18. Coakley FV, Kurhanewicz J, Lu Y et al. Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging. Radiology 2002; 223: 91-7
19. Hricak H, Wang L, Wei DC et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004; 100: 2655-63
20. Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24 to 0.7-cm3) spatial resolution. Radiology 1996; 198: 795-805
21. Males RG, Vigneron DB, Star-Lack J et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000; 43: 17-22
22. Mullerad M, Hricak H, Kuroiwa K et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol 2005; 174: 2158-63
23. Wang L, Hricak H, Kattan MW, Chen HN, Scardino PT, Kuroiwa K. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238: 597-603
24. Yu KK, Scheidler J, Hricak H et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999; 213: 481-8
25. Zakian KL, Sircar K, Hricak H et al. Correlation of proton MR spectroscopic imaging with Gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology 2005; 234: 804-14
26. Poulakis V, Witzsch U, de Vries R et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy. Urology 2004; 64: 1165-70
27. Qayyum A, Coakley FV, Lu Y et al. Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging. AJR Am J Roentgenol 2004; 183: 1079-83
28. Shukla-Dave A, Hricak H, Eberhardt SC et al. Chronic prostatitis: MR imaging and 1H MR spectroscopic imaging findings - initial observations. Radiology 2004; 231: 717-24
29. Zakian KL, Eberhardt S, Hricak H et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging - initial results. Radiology 2003; 229: 241-7
30. Aihara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994; 43: 60-7
31. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 1714-20
32. Harrell FE Jr. Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer Verlag, 2001: 568
33. Carter HB, Walsh PC, Landis P, Epstein JI. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results. J Urol 2002; 167: 1231-4
34. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol 2004; 171: 1520-4
35. Cunningham CH, Vigneron DB, Marjanska M et al. Sequence design for magnetic resonance spectroscopic imaging of prostate cancer at 3 T. Magn Reson Med 2005; 53: 1033-9
36. Scheenen TW, Gambarota G, Weiland E et al. Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T. Magn Reson Med 2005; 53: 1268-74